EGFR and non-small cell lung carcinoma: For instance, targeted treatment of NSCLC patients with EGFR mutations could improve their survival time (Ghafoor et al., 2018; Hsu et al., 2019), and targeted therapy for anaplastic lymphoma kinase positive disease could also improve the prognosis of patients with metastatic NSCLC (McCoach et al., 2017).